Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,710.50
Bid: 1,710.00
Ask: 1,711.00
Change: 5.50 (0.32%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,712.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Miners pull UK markets lower, but Smith & Nephew rises

Fri, 30th May 2014 11:34

- Mining stocks lower on iron ore, China concerns- Fenner issues profit warning- M&A continues to boost Smith & NephewtechMARK 2,820.23 +0.39%FTSE 100 6,860.62 -0.16%FTSE 250 16,039.31 +0.53%Weakness in the mining sector dragged the UK stock market from a two-week high on Friday, despite M&A speculation boosting the share prices of Smith & Nephew and Salamander Energy.Mining stocks were trading firmly in the red as iron ore prices were headed for their sixth consecutive monthly decline, the longest losing streak on record. Meanwhile, concerns about a slowdown in China were also having an impact on stocks, as well as a profit warning from polymer products group Fenner, which makes conveyor belts for the mining industry."[Chinese] government figures indicated manufacturing growth was weakening, contradicting recent signs of improvement in the economy and providing an excuse for some selling in raw materials," said Chris Beauchamp, Market Analyst at IG.The FTSE 100 was down 0.2% at 6,861 by midday after hitting 6,871.29 on Thursday, its highest close since May 14th when it reached a new 14-year high of 6,878.49.Investors were also focusing on a batch of mixed economic data from across the globe, including an improvement in consumer confidence in the UK, weak industrial production figures and stronger-than-expected inflation in Japan, and an unexpected dip in retail sales in Germany.Miners weigh on markets, Fenner plummetsRising iron ore supplies from Australia and Brazil have prompted a 9% fall in prices this month, with the value of the commodity having now fallen every month since December. This is the longest string of monthly losses since data from The Steel Index Ltd began in November 2008, according to Bloomberg. Diversified miners Anglo American, BHP Billiton and Rio Tinto were among the worst performers on the FTSE 100, with concerns over China also dampening sentiment.In another hit to sentiment in the mining industry, Fenner issued a profit warning, causing shares to sink sharply. The group said annual profits would be 10-15% below market expectations on the back of weakness in the US coal industry, prompting analysts at Numis Securities to downgrade the stock from 'add' to 'hold'.Meanwhile, solid fuel supplier and logistics group Hargreaves Services also fell after saying results from its Production Division will be below expectations this year due to "challenging trading conditions" in coke markets and delays.Medical device maker Smith & Nephew was on the rise as bid speculation continued to drive the stock higher. While US peer Stryker was forced to publicly deny reports that it was working on a bid for the company, its boss yesterday confirmed in an interview that the company had in fact been in the early stages of considering a transaction but was not ready to make an offer. UBS this morning added the stock to its 'M&A Watch List'.GlaxoSmithKline was fluctuating between gains and losses on rumours that it has approached a number of private equity firms to gauge the interest for a range of its older drugs as it attempts to refresh its portfolio. AIM-listed oil explorer Petroceltic was trading lower after giving investors a trio of "disappointing" updates from its international drilling programme. Meanwhile, sector peer Salamander Energy surged on reports that Cia Espanola de Petroleos SAU is looking to buy to company for €700m.DIY retailer Kingfisher was continuing to fall after an underwhelming first-quarter statement yesterday as Barclays Capital cut the shares to 'equal weight' and trimmed its target price.FTSE 100 - RisersSmith & Nephew (SN.) 1,055.00p +2.53%Coca-Cola HBC AG (CDI) (CCH) 1,390.00p +1.83%Admiral Group (ADM) 1,454.00p +1.82%Hammerson (HMSO) 601.00p +1.18%Whitbread (WTB) 4,182.00p +1.06%Persimmon (PSN) 1,340.00p +1.06%Sports Direct International (SPD) 800.00p +0.88%Land Securities Group (LAND) 1,071.00p +0.85%Sage Group (SGE) 415.10p +0.80%St James's Place (STJ) 786.00p +0.77%FTSE 100 - FallersRio Tinto (RIO) 3,104.50p -2.63%Anglo American (AAL) 1,505.50p -2.56%Fresnillo (FRES) 814.00p -2.52%BHP Billiton (BLT) 1,904.00p -1.88%Morrison (Wm) Supermarkets (MRW) 199.10p -1.53%Antofagasta (ANTO) 795.50p -1.12%Royal Mail (RMG) 512.50p -1.06%G4S (GFS) 250.30p -1.03%Kingfisher (KGF) 393.10p -0.98%Barratt Developments (BDEV) 356.50p -0.94%FTSE 250 - RisersOphir Energy (OPHR) 266.50p +4.02%Micro Focus International (MCRO) 843.00p +3.56%CSR (CSR) 597.50p +3.55%Euromoney Institutional Investor (ERM) 1,178.00p +3.51%Ocado Group (OCDO) 385.20p +3.41%Supergroup (SGP) 1,145.00p +3.25%Xaar (XAR) 847.00p +3.17%Afren (AFR) 154.10p +3.15%Rank Group (RNK) 160.80p +3.08%Perform Group (PER) 272.50p +2.83%FTSE 250 - FallersFenner (FENR) 349.30p -10.37%Paragon Group Of Companies (PAG) 376.80p -3.09%Evraz (EVR) 107.00p -2.01%Drax Group (DRX) 627.00p -1.49%Vedanta Resources (VED) 1,112.00p -1.33%Smith (DS) (SMDS) 318.90p -1.33%Tate & Lyle (TATE) 693.50p -1.14%Playtech (PTEC) 665.00p -1.12%Ferrexpo (FXPO) 137.50p -1.08%TalkTalk Telecom Group (TALK) 318.50p -1.06%BC
More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.